Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
September 15, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 15, 2003
- Kyowa Hakko Steps Up Patient Education Activities for Nocturnal Enuresis
September 15, 2003
- OTC NEWS IN BRIEF
September 15, 2003
- Fujisawa Establishes Centralized Drug Info Collection System
September 15, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 15, 2003
- Sankyo Licenses Olmesartan to Pfizer
September 15, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 15, 2003
- Kyorin Signs Drug Discovery Agreement with DPI of the US
September 15, 2003
- WORLD NEWS IN BRIEF
September 15, 2003
- Kissei Awaiting Approval of Dry Mouth Treatment Pilocarpine
September 15, 2003
- Janssen Aims to Boost Nizoral Sales to \3 Bil.
September 15, 2003
- Dentsu Develops New Advertising Tool for Drug, Med Device Makers
September 15, 2003
- 4 New Drugs Incl. Livalo Added to NHI List
September 15, 2003
- BUSINESS NEWS IN BRIEF
September 15, 2003
- Financial Results in 1st Quarter
September 8, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 8, 2003
- Korosho Budget Request for 2004 Totals \20 Trillion
September 8, 2003
- OTC NEWS IN BRIEF
September 8, 2003
- Korosho Calls For Attention to ADRs due to Tamiflu, Diovan
September 8, 2003
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…